New Paediatric Formulation of Tachipirina®

NCT ID: NCT06358586

Last Updated: 2024-04-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-09
• Study Completion Date: 2022-04-25

Brief Summary

This is a single centre, single dose, single-arm, open-label, palatability study.

The aim of the present study is to investigate the palatability of the newly developed Tachipirina® 120 mg/5 mL oral suspension with strawberry flavour. The study will be conducted in paediatric volunteers that represent the target population for this product.

Detailed Description

Twenty (20) healthy paediatric volunteers aged 6-17 years old inclusive will be enrolled in the study.

The primary end-point is to assess the palatability of the new strawberry flavour after single dose administration of the Investigation Medicine Product (IMP) through a questionnaire.

The secondary end-points is to monitor the safety and tolerability data after single dose administration of the Investigation Medicine Product (IMP).

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Tachipirina® 120 mg/5 mL oral suspension, strawberry flavour

All healthy paediatric volunteers administered with the mediation

Group Type: EXPERIMENTAL

Tachipirina® 120 mg/5 mL oral suspension, new flavour

Intervention Type: DRUG

A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.

Interventions

Tachipirina® 120 mg/5 mL oral suspension, new flavour

A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Sex and Age: males or females, 6-17 years old inclusive
• Body Mass Index: males/females not classified as overweight based on the applicable body mass index chart for sex and age
• Informed consent and assent: signed written informed consent by both parents/legal representatives unless only one has legal authority. Signed written informed assent for 14-17 years old inclusive adolescents or written informed assent for 11-13 years old inclusive children or oral informed assent for 6-10 years old inclusive children.
• Full comprehension: ability of the paediatric volunteer and parent(s)/legal representative(s) to comprehend the full nature and purpose of the study, including possible risks and side effects; ability of the paediatric volunteer and parent(s)/legal representative(s) to co-operate with the Investigator and to comply with the requirements of the entire study
• Ascertained tolerability to paracetamol: history of intake of Tachipirina® or its active ingredient, i.e., paracetamol, with no consequent adverse reaction

Exclusion Criteria

• Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
• Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
• Diseases: history of significant renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; mouth lesions or any other oral mucosa alteration that may interfere with the aim of the study according to the Investigator's opinion
• Medications: medications, including over the counter medications and herbal remedies for 2 weeks before the start of the study that may interfere with the aim of the study according to the Investigator's opinion. Hormonal contraceptives for child-bearing potential females (i.e., post-menarche) will be allowed
• Tobacco: smokers will not be admitted
• Investigative drug studies: participation in the evaluation of any investigational medicinal product for 3 months before this study. The 3-month interval will be calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
• Diet: abnormal diets or substantial changes in eating habits in the 4 weeks before this study that may interfere with the aim of the study according to the Investigator's opinion
• SARS-CoV-2 test: positive Covid-19 Antigen Rapid Test at screening of paediatric volunteer or parent(s)/legal representative(s)
• Drug test: only for adolescents 12-17 years old inclusive, positive drug test at screening
• Alcohol breath test: only for adolescents 12-17 years old inclusive, positive alcohol breath test at screening
• Pregnancy: only for child-bearing potential females (i.e., post-menarche), positive or missing pregnancy test at screening

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cross S.A.

INDUSTRY

Sponsor Role: collaborator

Aziende Chimiche Riunite Angelini Francesco S.p.A

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Milko Radicioni

Role: PRINCIPAL_INVESTIGATOR

CROSS Research S.A. - Phase I Unit,

Locations

CROSS Research S.A. - Phase I Unit,

Arzo, , Switzerland

Countries

Switzerland

Other Identifiers

CRO-PK-21-356

Identifier Type: OTHER

Identifier Source: secondary_id

044(H)MD21176

Identifier Type: -

Identifier Source: org_study_id